[Dynamics of serum IL-17A, IL-17F and IL-23 in patients with inflammatory bowel disease].
The analysis of the levels of proinflammatory cytokines IL-17A, IL-17F and IL-23 allow to evaluate the effectiveness of the therapy:, so MSCs systemic immunosuppressive therapy and corticosteroids increasingly reduces the level of all studied proinflammatory cytokines, while in therapy with infliximab, a selective immunosuppressive agent, significantly less effect on the level of proinflammatory cytokines IL-17A, IL-17F and IL-23.